Covista Inc. (CVSA)
NYSEConsumer DiscretionaryEducation & Training ServicesSnapshot 2026-09-04
$128.09+0.35%
Close 2026-09-04 · 1-day change
NYSEConsumer DiscretionaryEducation & Training ServicesSnapshot 2026-09-04
Broken: Primary pillar broken — Adjusted EPS at or above $8.05 in FY 2026: FY26 EPS guidance mid $8.05 vs $8.05 target.
Covista raises its EPS guidance to about $8.05 for fiscal 2026, showing strong profit growth. Revenue guidance is increased to nearly $1.94 billion, reflecting steady sales growth of about 8% to 9%. Operating income rose to $111 million in 2026-Q2, showing better efficiency. The company beat Q3 earnings with EPS of $1.98, 15% above estimates.
Growth could slow if revenue or EPS fall below guidance. Litigation and recent negative news may pressure margins or cash flow. If operating income fails to improve, profit growth may stall.
The stock trades about 18% below our valuation level, with analysts expecting roughly 8.5% revenue growth next year. Our view aligns with this growth but sees upside if operating income and EPS continue rising.
Breaks if: Adjusted EPS falls below $7.9 in FY 2026
Breaks if: Operating income falls below $90 million in any quarter
Breaks if: Revenue falls below $1.92 billion in FY 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth in the healthcare sector. The current thesis state is cautious, as recent performance has shown some weakness despite management's commitment to increasing guidance.
The market seems to have a neutral view on CVSA's valuation, with expectations slightly below what might be justified based on its recent performance. The company trades at a premium compared to peers, indicating that some growth is already priced in.
Management has shown robust earnings quality and is on track to increase revenue and adjusted EPS guidance for fiscal year 2026. However, there are mixed signals regarding the expansion into adjacent healthcare domains and workforce pipeline building, which may impact future performance.
The thesis hinges on management's ability to maintain or improve guidance in the upcoming earnings call and the performance of sector bellwethers that could influence overall market sentiment. Additionally, inflation trends and their impact on consumer discretionary spending will be crucial.
The most important moves since the prior daily snapshot.
Valuation rose by 11.8 points (from 47.5 to 59.3).
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, CVSA's performance will depend on effective execution of its growth strategies and external economic factors. Not investment advice.